Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Efmoroctocog-alfa/Moroctocog-alfa/Octocog-alfa

Development of inhibitors

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Alabbas F, et al. Successful Long-Term Tolerance in Patients with Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis: A Single Saudi Center Experience. Research and Practice in Thrombosis and Haemostasis 7 (Suppl.) : 1129-1130, Oct 2023. Available from: URL: https://dx.doi.org/10.1016/j.rpth.2023.101969 [abstract] Alabbas F, et al. Successful Long-Term Tolerance in Patients with Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis: A Single Saudi Center Experience. Research and Practice in Thrombosis and Haemostasis 7 (Suppl.) : 1129-1130, Oct 2023. Available from: URL: https://dx.doi.org/10.1016/j.rpth.2023.101969 [abstract]
Metadaten
Titel
Efmoroctocog-alfa/Moroctocog-alfa/Octocog-alfa
Development of inhibitors
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-54052-9

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Methotrexate

Case report

Heparin

Case report

Rivaroxaban